Effect of hypermagnesemia on circulating plasma parathyroid hormone in patients on regular hemodialysis therapy

Magnesium. 1984;3(1):1-7.


This study was designed to assess the influence of magnesium on circulating plasma immunoreactive parathyroid hormone (iPTH) in end-stage renal disease. 20 patients receiving regular hemodialysis therapy underwent plasma measurements of iPTH and 25-hydroxycholecalciferol (25-OHCC) concentrations before and 10 weeks after the magnesium concentration in the dialysate was increased from 0.75 to 1.50 mmol/l. This resulted in a 36% rise in the mean predialysis plasma magnesium concentration from 1.25 to 1.70 mmol/l (p less than 0.001) and a 23% fall in the mean plasma iPTH concentration from 546 to 418 ng/l (p less than 0.001). Mean plasma concentrations for calcium, phosphate, and 25-OHCC also decreased, but these changes were not significant. In conclusion, we have demonstrated that a rise in plasma magnesium concentration from elevated to significantly higher levels reduces circulating plasma iPTH in normocalcemic uremic patients with initially both normal and raised plasma PTH levels.

MeSH terms

  • Adult
  • Aged
  • Animals
  • Calcifediol / blood
  • Calcium / blood
  • Humans
  • Hyperparathyroidism / etiology
  • Kidney Failure, Chronic / complications
  • Magnesium / blood
  • Magnesium / pharmacology*
  • Middle Aged
  • Parathyroid Hormone / blood*
  • Phosphates / blood
  • Renal Dialysis*


  • Parathyroid Hormone
  • Phosphates
  • Magnesium
  • Calcifediol
  • Calcium